Lymphoprep™

Density gradient medium for the isolation of mononuclear cells

New catalog numbers, same high quality product! On December 1, 2024, the catalog numbers for the 250 mL and 500 mL sizes will be changed to Catalog #18060 and Catalog #18061, respectively. Catalog numbers for the 1000 mL and 3000 mL sizes will remain unchanged; however, the bottles within these bundled formats will have labels with the new catalog numbers.

Lymphoprep™

Density gradient medium for the isolation of mononuclear cells

Catalog #
(Select a product)
Density gradient medium for the isolation of mononuclear cells
Request Pricing

Overview

Reliably isolate mononuclear cells from peripheral blood, cord blood, or bone marrow with Lymphoprep™—a cost-effective alternative to Ficoll-Paque™. Use this density gradient medium for rapid, simple, and reliable cell isolation from most blood samples obtained from normal individuals and patients. You can substitute Lymphoprep™ for Ficoll-Paque™ without changing your existing protocols and achieve similar cell purity and recovery rates. This medium is fully compatible with both SepMate™ and RosetteSep™. Formulated with sodium diatrizoate (9.1% w/v) and polysaccharide (5.7% w/v), Lymphoprep™ has a density of 1.077 g/ml.
Contains
• Sodium diatrizoate (9.1% w/v)
• Polysaccharide (5.7% w/v)
• Other ingredients
Subtype
Density Gradient Media
Cell Type
Mononuclear Cells
Species
Human
Sample Source
Bone Marrow, Cord Blood, Whole Blood
Selection Method
Negative
Application
Cell Isolation
Brand
Lymphoprep
Area of Interest
Immunology

Data Figures

Figure 1. Purity and Recovery of Cells from Whole Blood When Using Cost-Effective Lymphoprep™ is Comparable to Using Ficoll-Paque™ PLUS

(A) Density gradient centrifugation of peripheral whole blood using Lymphoprep™ results in similar cell purity of mononuclear cells including T cells, B cells, NK cells and monocytes compared to Ficoll-Paque™ PLUS. (B) The recovery of total mononuclear cells and CD45+ cells is also similar. (n = 5, Mean ± SD).

Figure 2. Purity and Recovery of Cells from Cord Blood When Using Cost-Effective Lymphoprep™ is Comparable to Using Ficoll-Paque™ PLUS

(A) Density Gradient centrifugation of cord blood using Lymphoprep™ results in similar cell purity of mononuclear cells including T cells, B cells, NK cells and monocytes compared to Ficoll-Paque™ PLUS. (B) The recovery of total mononuclear cells and CD45+ cells is also similar. (n = 4, Mean ± SD).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
Lymphoprep™
Catalog #
07861, 07851, 07801, 07811
Lot #
All
Language
Multi
Product Name
Lymphoprep™
Catalog #
07861, 07851, 07801, 07811
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Lymphoprep™
Catalog #
07861, 07851, 07801, 07811
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (30)

Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. Y. Chen et al. Blood advances 2020 oct

Abstract

Murine models of myeloid neoplasia show how leukemia infiltration alters the hematopoietic stem cell (HSC) niche to reinforce malignancy at the expense of healthy hematopoiesis. However, little is known about the bone marrow architecture in humans and its impact on clinical outcome. Here, we dissect the bone marrow niche in patients with acute myeloid leukemia (AML) at first diagnosis. We combined immunohistochemical stainings with global gene expression analyses from these AML patients and correlated them with clinical features. Mesenchymal stem and progenitor cells (MSPCs) lost quiescence and significantly expanded in the bone marrow of AML patients. Strikingly, their HSC- and niche-regulating capacities were impaired with significant inhibition of osteogenesis and bone formation in a cell contact-dependent manner through inhibition of cytoplasmic $\beta$-catenin. Assessment of bone metabolism by quantifying peripheral blood osteocalcin levels revealed 30{\%} lower expression in AML patients at first diagnosis than in non-leukemic donors. Furthermore, patients with osteocalcin levels ≤11 ng/mL showed inferior overall survival with a 1-year survival rate of 38.7{\%} whereas patients with higher osteocalcin levels reached a survival rate of 66.8{\%}. These novel insights into the human AML bone marrow microenvironment help translate findings from preclinical models and detect new targets which might pave the way for niche-targeted therapies in AML patients.
Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. S. J. Wang et al. Science advances 2020 may

Abstract

Interpreting how multicellular interactions in the tumor affect resistance pathways to BRAF and MEK1/2 MAPK inhibitors (MAPKi) remains a challenge. To investigate this, we profiled global ligand-receptor interactions among tumor and stromal/immune cells from biopsies of MAPK-driven disease. MAPKi increased tumor-associated macrophages (TAMs) in some patients, which correlated with poor clinical response, and MAPKi coamplified bidirectional tumor-TAM signaling via receptor tyrosine kinases (RTKs) including AXL, MERTK, and their ligand GAS6. In xenograft tumors, intravital microscopy simultaneously monitored in situ single-cell activities of multiple kinases downstream of RTKs, revealing MAPKi increased TAMs and enhanced bypass signaling in TAM-proximal tumor cells. As a proof-of-principle strategy to block this signaling, we developed a multi-RTK kinase inhibitor nanoformulation that accumulated in TAMs and delayed disease progression. Thus, bypass signaling can reciprocally amplify across nearby cell types, offering new opportunities for therapeutic design.
A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus. R. Ganugula et al. Science advances 2020 jun

Abstract

Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity. We hypothesized that CD71 (transferrin receptor 1)-directed delivery of CsA to the lymphatic system would improve SLE outcomes in a murine model. We synthesized biodegradable, ligand-conjugated nanoparticles [P2Ns-gambogic acid (GA)] targeting CD71. GA conjugation substantially increased nanoparticle association with CD3+ or CD20+ lymphocytes and with intestinal lymphoid tissues. In orally dosed MRL-lpr mice, P2Ns-GA-encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti-double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.
New catalog numbers, same high quality product! On December 1, 2024, the catalog numbers for the 250 mL and 500 mL sizes will be changed to Catalog #18060 and Catalog #18061, respectively. Catalog numbers for the 1000 mL and 3000 mL sizes will remain unchanged; however, the bottles within these bundled formats will have labels with the new catalog numbers.